Zacks Investment Research on MSN2d
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...
pharmaphorum2d
Roche ends the 30-year US hiatus in new stroke drugs
In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...
Fierce Pharma3d
Roche gains label expansion for heart attack medicine TNKase to treat acute ischemic stroke
Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...
BioSpace2d
Roche Continues Regulatory Run With Acute Stroke Expansion for Heart Attack Drug
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...
PMLive1d
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
GlobalData on MSN2d
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Contract Pharma2d
Genentech’s TNKase Approved by FDA for Treatment of Strokes
The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...
Roche peut commercialiser le TNKase aux Etats-Unis
Genentech, filiale américaine du géant pharmaceutique bâlois Roche va pouvoir commercialiser aux Etats-Unis, le TNKase un ...
La FDA approuve TNKase de Genentech dans l'AVC ischémique aigu chez l'adulte
Genentech : * FDA APPROVES GENENTECHS TNKASE® IN ACUTE ISCHEMIC STROKE IN ADULTS Source text : Plus d'informations sur les ...